Cardiovascular Risk in Early Psychosis: Relationship with Inflammation and Clinical Features 6 Months after Diagnosis
Resumen: Background: We aimed to investigate the state of cardiovascular risk/protection factors in early psychosis patients.
Methods: A total 119 subjects were recruited during the first year after their first episode of psychosis. Eighty-five of these subjects were followed during the next 6 months. Cardiovascular risk/protection factors were measured in plasma and co-variated by sociodemographic/clinical characteristics. Multiple linear regression models detected the change of each biological marker from baseline to follow-up in relation to clinical scales, antipsychotic medication, and pro-/antiinflammatory mediators.
Results: Glycosylated hemoglobin is a state biomarker in first episode of psychosis follow-up patients and inversely correlated to the Global Assessment of Functioning scale. We found opposite alterations in the levels of VCAM-1 and E-selectin in first episode of psychosis baseline conditions compared with control that were absent in the first episode of psychosis follow-up group. Adiponectin levels decreased in a continuum in both pathological time points studied. E-Selectin plasma levels were inversely related to total antipsychotic equivalents and adiponectin levels inversely co-related to the Global Assessment of Functioning scale. Finally, adiponectin levels were directly related to antiinflammatory nuclear receptor PPARy expression in first episode of psychosis baseline conditions and to proinflammatory nuclear factor nuclear factor kB activity in follow-up conditions, respectively.
Conclusions: Our results support the need for integrating cardiovascular healthcare very early after the first episode of psychosis.

Idioma: Inglés
DOI: 10.1093/ijnp/pyx110
Año: 2018
Publicado en: International Journal of Neuropsychopharmacology 21, 5 (2018), 410-422
ISSN: 1461-1457

Factor impacto JCR: 4.207 (2018)
Categ. JCR: CLINICAL NEUROLOGY rank: 40 / 199 = 0.201 (2018) - Q1 - T1
Categ. JCR: PSYCHIATRY rank: 30 / 146 = 0.205 (2018) - Q1 - T1
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 45 / 266 = 0.169 (2018) - Q1 - T1
Categ. JCR: NEUROSCIENCES rank: 73 / 266 = 0.274 (2018) - Q2 - T1

Factor impacto SCIMAGO: 1.846 - Pharmacology (Q1) - Psychiatry and Mental Health (Q1) - Pharmacology (medical) (Q1)

Tipo y forma: Article (Published version)
Área (Departamento): Area Psiquiatría (Dpto. Medicina, Psiqu. y Derm.)

Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes.


Exportado de SIDERAL (2020-01-08-09:30:09)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Articles



 Record created 2018-06-18, last modified 2020-01-08


Versión publicada:
 PDF
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)